Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study.

Tazaki Y, Sakai F, Otomo E, Kutsuzawa T, 
Kameyama M, Omae T, Fujishima M, Sakuma A.

Department of Medicine, 
Kitasato University, Sagamihara, Japan.
Stroke 1988 Feb;19(2):211-6

Abstract

A multicenter double-blind placebo-controlled study of cytidine 5'-diphosphocholine (CDP-choline) was conducted to evaluate possible clinical benefits of the drug in patients with acute, moderate to severe cerebral infarction. The patients included also suffered from moderate to mild disturbances of consciousness, and all were admitted within 14 days of the ictus. Patients were allocated randomly to treatment with either CDP-choline (1,000 mg/day i.v. once daily for 14 days) or with placebo (physiological saline). One hundred thirty-three patients received CDP-choline treatment, and 139 received placebo. The group treated with CDP-choline showed significant improvements in level of consciousness compared with the placebo-treated group, and CDP-choline was an entirely safe treatment.

 | Home | Order |

 1.   CDP choline  may be useful in the treatment of Alzheimer's
 2.   CDP choline  therapeutic effects in Alzheimer's
 3.   CDP choline  choline  effects on cognition in patients with Alzheimer's
 4.   CDP choline  significant improvement in Alzheimer's after 1 month  
 5.   CDP choline  improved mental performance in Alzheimer's
 6.   CDP choline  improvement in glaucoma
 7.   CDP choline  therapeutic value in the treatment of glaucoma
 8.   CDP choline  improved retinal responses in patients with glaucoma
 9.   CDP choline  in acute ischemic stroke
10.  CDP choline  randomized trial in acute ischemic stroke
11.  CDP choline  treatment after traumatic brain injury
12.  CDP choline  action and effects in ischemic brain injury